Top

Published in:

Open Access 23-06-2022 | Human Papillomavirus | Special Article

Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Authors: José Trigo, Mónica García-Cosío, Almudena García-Castaño, Montserrat Gomà, Ricard Mesia-Nin, Elena Ruiz-Bravo, Ainara Soria-Rivas, Paola Castillo, Irene Braña-García, Margarita Alberola-Ferranti

Published in: Clinical and Translational Oncology | Issue 10/2022

Abstract

The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(7):845–52. https://doi.org/10.1200/jco.2012.43.6097.CrossRef

Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99–14). Int J Radiat Oncol Biol Phys. 2008;71(5):1351–5. https://doi.org/10.1016/j.ijrobp.2008.04.006.CrossRefPubMedPubMedCentral

Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1–12. https://doi.org/10.1016/s0360-3016(99)00558-1.CrossRefPubMed

Carlander AF, Jakobsen KK, Bendtsen SK, Garset-Zamani M, Lynggaard CD, Jensen JS, et al. A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide. Viruses. 2021. https://doi.org/10.3390/v13071326.CrossRefPubMedPubMedCentral

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. https://doi.org/10.1056/NEJMoa0912217.CrossRefPubMedPubMedCentral

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.CrossRefPubMed

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67. https://doi.org/10.1016/S0140-6736(18)31999-8.CrossRefPubMed

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. https://doi.org/10.1056/NEJMoa1602252.CrossRefPubMedPubMedCentral

10.

Brose MS, Shen L, Tan DSW, Kummar S, Lin JJ, McDermott R, et al. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer. Ann Oncol. 2021;32(suppl_5):S583–620. https://doi.org/10.1016/annonc/annonc699.CrossRef

11.

Gilardi M, Wang Z, Proietto M, Chillà A, Calleja-Valera JL, Goto Y, et al. Tipifarnib as a precision therapy for HRAS-mutant head and neck squamous cell carcinomas. Mol Cancer Ther. 2020;19(9):1784–96. https://doi.org/10.1158/1535-7163.MCT-19-0958.CrossRefPubMedPubMedCentral

12.

Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386–98. https://doi.org/10.1093/annonc/mdx304.CrossRefPubMed

13.

Faraji F, Eisele DW, Fakhry C. Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2017;2(1):10–8. https://doi.org/10.1002/lio2.37.CrossRefPubMedPubMedCentral

14.

Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol. 2014;25(4):801–7. https://doi.org/10.1093/annonc/mdt574.CrossRefPubMedPubMedCentral

15.

Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015;33(8):836–45. https://doi.org/10.1200/JCO.2014.58.6412.CrossRefPubMed

16.

O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51. https://doi.org/10.1016/S1470-2045(15)00560-4.CrossRefPubMed

17.

Haughey BH, Sinha P, Kallogjeri D, Goldberg RL, Lewis JS, Piccirillo JF, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol. 2016;62:11–9. https://doi.org/10.1016/j.oraloncology.2016.09.004.CrossRefPubMedPubMedCentral

18.

Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med. 2017;142(5):559–97. https://doi.org/10.5858/arpa.2017-0286-CP.CrossRefPubMed

19.

Bussu F, Ragin C, Boscolo-Rizzo P, Rizzo D, Gallus R, Delogu G, et al. HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck. 2019;41(4):1104–11. https://doi.org/10.1002/hed.25591.CrossRefPubMed

20.

Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, et al. Human papillomavirus testing in head and neck carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol. 2018;36(31):3152–61. https://doi.org/10.1200/JCO.18.00684.CrossRefPubMed

21.

Jalaly JB, Hosseini SM, Shafique K, Baloch ZW. Current status of p16 immunohistochemistry and HPV testing in fine needle aspiration specimens of the head and neck. Acta Cytol. 2020;64(1–2):30–9. https://doi.org/10.1159/000496158.CrossRefPubMed

22.

Mehanna H, Sanz MT, Tous S, Brooks J, von Buchwald C, Mena M, et al. Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC Study. Ann Oncol. 2020;31(suppl_4):S599–628. https://doi.org/10.1016/annonc/annonc277.CrossRef

23.

Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011;17(19):6262. https://doi.org/10.1158/1078-0432.CCR-11-0388.CrossRefPubMedPubMedCentral

24.

Bigelow EO, Seiwert TY, Fakhry C. Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: current state and future directions. Oral Oncol. 2020;105:104652. https://doi.org/10.1016/j.oraloncology.2020.104652.CrossRefPubMedPubMedCentral

25.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50. https://doi.org/10.1016/S0140-6736(18)32779-X.CrossRefPubMed

26.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60. https://doi.org/10.1016/S0140-6736(18)32752-1.CrossRefPubMedPubMedCentral

27.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27. https://doi.org/10.1056/NEJMoa0802656.CrossRefPubMed

28.

EMA. Pembrolizumab European Assessment Report EMA/CHMP/591139/2019. 2019. https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf. Accessed Nov 2021.

29.

Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up^†. Ann Oncol. 2020;31(11):1462–75. https://doi.org/10.1016/j.annonc.2020.07.011.CrossRefPubMed

30.

Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol. 2021;23(5):913–21. https://doi.org/10.1007/s12094-020-02533-1.CrossRefPubMedPubMedCentral

31.

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184. https://doi.org/10.1186/s40425-019-0662-5.CrossRefPubMedPubMedCentral

32.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51. https://doi.org/10.1016/j.oraloncology.2018.04.008.CrossRefPubMedPubMedCentral

33.

Cerbelli B, Girolami I, Eccher A, Costarelli L, Taccogna S, Scialpi R, et al. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology. 2021. https://doi.org/10.1111/his.14562.CrossRefPubMedPubMedCentral

34.

Crosta S, Boldorini R, Bono F, Brambilla V, Dainese E, Fusco N, et al. PD-L1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols. Cancers. 2021;13(2):292.CrossRef

35.

de Ruiter EJ, Mulder FJ, Koomen BM, Speel E-J, van den Hout MFCM, de Roest RH, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34(6):1125–32. https://doi.org/10.1038/s41379-020-0644-7.CrossRefPubMed

36.

Ionescu DN, Downes MR, Christofides A, Tsao MS. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr Oncol. 2018;25(3):e209–16. https://doi.org/10.3747/co.25.4031.CrossRefPubMedPubMedCentral

37.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4–17. https://doi.org/10.1038/s41379-019-0327-4.CrossRefPubMed

38.

Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0.CrossRefPubMed

39.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

40.

Tsao SW, Tsang CM, Lo KW. Epstein–Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160270. https://doi.org/10.1098/rstb.2016.0270.CrossRefPubMedPubMedCentral

41.

Coghill AE, Hsu W-L, Pfeiffer RM, Juwana H, Yu KJ, Lou P-J, et al. Epstein–Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Cancer Epidemiol Biomark Prev. 2014;23(7):1213–9. https://doi.org/10.1158/1055-9965.EPI-13-1262.CrossRef

42.

Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22. https://doi.org/10.1056/NEJMoa1701717.CrossRefPubMed

43.

Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A, et al. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019;88:145–52. https://doi.org/10.1016/j.oraloncology.2018.11.020.CrossRefPubMed

44.

Waltonen JD, Ozer E, Hall NC, Schuller DE, Agrawal A. Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg. 2009;135(10):1024–9. https://doi.org/10.1001/archotol.128.1.58.CrossRefPubMed

45.

Pusztaszeri MP, Faquin WC. Cytologic evaluation of cervical lymph node metastases from cancers of unknown primary origin. Semin Diagn Pathol. 2015;32(1):32–41. https://doi.org/10.1053/j.semdp.2014.12.002.CrossRefPubMed

46.

Maghami E, Ismaila N, Alvarez A, Chernock R, Duvvuri U, Geiger J, et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol. 2020;38(22):2570–96. https://doi.org/10.1200/JCO.20.00275.CrossRefPubMed

47.

Tribius S, Hoffmann AS, Bastrop S, Görögh T, Haag J, Röcken C, et al. HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncol. 2012;48(11):1178–84. https://doi.org/10.1016/j.oraloncology.2012.05.022.CrossRefPubMed

48.

Yeoh CC, Dabab N, Rigby E, Chhikara R, Akaev I, Gomez RS, et al. Androgen receptor in salivary gland carcinoma: a review of an old marker as a possible new target. J Oral Pathol Med. 2018;47(7):691–5. https://doi.org/10.1111/jop.12741.CrossRefPubMed

49.

Dalin MG, Watson PA, Ho AL, Morris LGT. Androgen receptor signaling in salivary gland cancer. Cancers. 2017;9(2):17. https://doi.org/10.3390/cancers9020017.CrossRefPubMedCentral

50.

Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019;8(17):7322–9. https://doi.org/10.1002/cam4.2602.CrossRefPubMedPubMedCentral

51.

Xu B, Dogan S, Al Rasheed MRH, Ghossein R, Katabi N. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum Pathol. 2019;93:30–6. https://doi.org/10.1016/j.humpath.2019.08.007.CrossRefPubMedPubMedCentral

52.

Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979–84. https://doi.org/10.1093/annonc/mdx771.CrossRefPubMed

53.

van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma. Eur J Cancer. 2019;110:62–70. https://doi.org/10.1016/j.ejca.2018.12.035.CrossRefPubMed

54.

Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sørensen M. HER2 Positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis. Front Oncol. 2021;11:693394. https://doi.org/10.3389/fonc.2021.693394.CrossRefPubMedPubMedCentral

55.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.CrossRefPubMed

56.

Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2018;37(2):125–34. https://doi.org/10.1200/JCO.18.00545.CrossRefPubMed

57.

Meric-Bernstam F, Hainsworth J, Bose R, Iii HAB, Friedman CF, Kurzrock R, et al. MyPathway HER2 basket study: pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):3004.CrossRef

58.

Li BT, Shen R, Offin M, Buonocore DJ, Myers ML, Venkatesh A, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial. J Clin Oncol. 2019;37(15_suppl):6001. https://doi.org/10.1200/JCO.2019.37.15_suppl.6001.CrossRef

59.

Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, et al. Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults. Curr Oncol. 2021;28(1):523–48. https://doi.org/10.3390/curroncol28010053.CrossRefPubMedPubMedCentral

60.

Garrido P, Hladun R, de Álava E, Álvarez R, Bautista F, López-Ríos F, et al. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. Clin Transl Oncol. 2021;23(8):1529–41. https://doi.org/10.1007/s12094-021-02558-0.CrossRefPubMedPubMedCentral

61.

Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46. https://doi.org/10.1038/s41379-019-0324-7.CrossRefPubMed

62.

Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40. https://doi.org/10.1016/S1470-2045(19)30856-3.CrossRefPubMedPubMedCentral

63.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82. https://doi.org/10.1016/S1470-2045(19)30691-6.CrossRefPubMed

64.

Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 2010;1(1):2–27. https://doi.org/10.4161/sgtp.1.1.12178.CrossRefPubMedPubMedCentral

65.

Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82. https://doi.org/10.1038/nrc.2018.11.CrossRefPubMed

66.

Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(17):1856–64. https://doi.org/10.1200/jco.20.02903.CrossRef

67.

Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (New York, NY). 2011;333(6046):1154–7. https://doi.org/10.1126/science.1206923.CrossRef

68.

Liu YF, Chiang SL, Lin CY, Chang JG, Chung CM, Ko AM, et al. Somatic mutations and genetic variants of NOTCH1 in head and neck squamous cell carcinoma occurrence and development. Sci Rep. 2016;6:24014. https://doi.org/10.1038/srep24014.CrossRefPubMedPubMedCentral

69.

Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, et al. PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K/mTOR inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(11):3329–40. https://doi.org/10.1158/1078-0432.Ccr-18-3276.CrossRef

70.

Marquard FE, Jücker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2020;172:113729. https://doi.org/10.1016/j.bcp.2019.113729.CrossRefPubMed

71.

Brisson RJ, Kochanny S, Arshad S, Dekker A, DeSouza JA, Saloura V, et al. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019;41(11):3842–9. https://doi.org/10.1002/hed.25910.CrossRefPubMedPubMedCentral

72.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323–35. https://doi.org/10.1016/s1470-2045(17)30064-5.CrossRefPubMed

73.

Chuang FC, Wang CC, Chen JH, Hwang TZ, Yeh SA, Su YC. PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy. PLoS One. 2021;16(1): e0245715. https://doi.org/10.1371/journal.pone.0245715.CrossRefPubMedPubMedCentral

74.

Day D, Prawira A, Spreafico A, Waldron J, Karithanam R, Giuliani M, et al. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncol. 2020;108: 104753. https://doi.org/10.1016/j.oraloncology.2020.104753.CrossRefPubMed

75.

Dunn LA, Riaz N, Fury MG, McBride SM, Michel L, Lee NY, et al. A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III–IVB head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;106(3):564–70. https://doi.org/10.1016/j.ijrobp.2019.09.050.CrossRefPubMed

76.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21(1):81–5. https://doi.org/10.1038/nm.3773.CrossRefPubMed

77.

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1): e000442. https://doi.org/10.1136/esmoopen-2018-000442.CrossRefPubMedPubMedCentral

78.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65. https://doi.org/10.1016/s1470-2045(16)30066-3.CrossRefPubMed

79.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018. https://doi.org/10.1172/jci.insight.98811.CrossRefPubMedPubMedCentral

80.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930–40. https://doi.org/10.1172/jci91190.CrossRefPubMedPubMedCentral

81.

Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74. https://doi.org/10.1056/NEJMra0707704.CrossRefPubMed

82.

Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, NY). 2011;333(6046):1157–60. https://doi.org/10.1126/science.1208130.CrossRef

83.

Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, et al. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 2013;35(3):454–63. https://doi.org/10.1002/hed.23100.CrossRefPubMed

84.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9. https://doi.org/10.1056/NEJMoa1714448.CrossRefPubMedPubMedCentral

85.

Skálová A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol. 2018;42(2):e11–27. https://doi.org/10.1097/pas.0000000000000980.CrossRefPubMed

86.

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–505. https://doi.org/10.1016/j.annonc.2020.07.014.CrossRefPubMed

87.

Roy S, Coldren C, Karunamurthy A, Kip NS, Klee EW, Lincoln SE, et al. Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines: a Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn JMD. 2018;20(1):4–27. https://doi.org/10.1016/j.jmoldx.2017.11.003.CrossRefPubMed

88.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, et al. Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(12):2939–49. https://doi.org/10.1158/1078-0432.Ccr-15-2314.CrossRef

Title: Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Authors: José Trigo
Mónica García-Cosío
Almudena García-Castaño
Montserrat Gomà
Ricard Mesia-Nin
Elena Ruiz-Bravo
Ainara Soria-Rivas
Paola Castillo
Irene Braña-García
Margarita Alberola-Ferranti
Publication date: 23-06-2022
Publisher: Springer International Publishing
Keywords: Human Papillomavirus
Epstein-Barr Virus
Pathology
Biomarkers
Androgens
Published in: Clinical and Translational Oncology / Issue 10/2022
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-022-02856-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2022

CDC7 as a novel biomarker and druggable target in cancer

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors

FOXD2-AS1 acts an oncogene in esophageal squamous cell carcinoma through sponging miR-204-3p

Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology

Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer